cfDNA as a surrogate marker for COVID-19 severity in patients with influenza-like symptoms with and without SARS-CoV-2 infections in general practice: a study protocol for a prospective cohort study
Introduction The clinical course of patients with a SARS-CoV-2 (COVID-19) infection varies widely, from symptom-free to severe courses that can lead to death. Laboratory values of SARS-CoV-2 patients such as lymphocyte counts or C-reactive protein (CRP) do not allow a prediction of the actual course...
Saved in:
Main Authors: | Dorothea Dehnen, Elmo Neuberger, Jürgen in der Schmitten, Ekaterini Giagkou, Perikles Simon, Suzan Botzenhardt |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-06-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/6/e058647.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non‐small cell lung cancer patients
by: Yidan Ma, et al.
Published: (2024-09-01) -
Interfacial cfDNA Enrichment and Amplification with On‐Chip Thermoplasmonics for Highly Sensitive Cancerous Liquid Biopsy
by: Danhua Wang, et al.
Published: (2025-01-01) -
5‐Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma
by: Weiwei Xie, et al.
Published: (2024-12-01) -
The clinical value of Serum hyaluronic acid, procollagen III, N-terminal propeptide levels sST2 and cfDNA in predicting the myocardial damage in children with severe pneumonia
by: Haoran Jia, et al.
Published: (2025-01-01) -
Evaluation of a flow cytometry-based surrogate assay (FlowSA) for the detection of SARS-CoV-2 in clinical samples
by: Vinit Upasani, et al.
Published: (2025-02-01)